Table 9.

Clinical trials involving TNF antagonist for cancer therapy

Products	NCT number	Cancer types	Combination partners	Phase	Status
Infliximab	NCT05034536	Melanoma	Pembrolizumab	II	Recruiting
	NCT04407247	Genitourinary Cancer or Melanoma	Monotherapy	I/II	Recruiting
	NCT04305145	Melanoma	Monotherapy	II	Unknown status
	NCT04082910	Solid and Hematological Malignancy	Metoprolol	I/II	Recruiting
	NCT03293784	Melanoma	Nivolumab and Ipilimumab	I	Completed
	NCT02763761	RCC, Melanoma, and Lung Cancer	Monotherapy	II	Withdrawn
	NCT00112749	Breast Cancer	Monotherapy	II	Terminated
	NCT00060502	Pancreatic Neoplasms	Gemcitabine	II	Completed
	NCT00040885	Lung Cancer	Docetaxel	III	Completed
Etanercept	NCT00201812	Solid Tumors	Docetaxel and Dexamethasone	I	Completed
	NCT00046904	Solid Tumors	Monotherapy	III	Completed
	NCT00201838	Pancreatic Neoplasms	Gemcitabine	I/II	Completed
	NCT03792841	Prostate Cancer	Acapatamab	I	Completed
	NCT00127387	Solid Tumors	Monotherapy	II/III	Terminated
	NCT04082910	Solid and Hematological Malignancy	Metoprolol	I/II	Recruiting
Adalimumab	NCT02516774	Anaplastic Thyroid Cancers	Monotherapy	I	Withdrawn
Golimumab	NCT05960578	Prostate Cancer	Apalutamide	II	Recruiting

Note: RCC renal cell carcinoma